Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two Part Study in Japanese Patients With mCRC, Consisting of an Open-label Phase I Part to Assess the Safety and Tolerability of Cediranib (AZD2171) in Combination With FOLFOX Followed by a Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of Cediranib (AZD2171) in Combination With FOLFOX

NCT00494221 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00494221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00494221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two Part Study in Japanese Patients With mCRC, Consisting of an Open-label Phase I Part to Assess the Safety and Tolerability of Cediranib (AZD2171) in Combination With FOLFOX Followed by a Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of Cediranib (AZD2171) in Combination With FOLFOX
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2007
Completion date
August 31, 2012
Enrollment
172 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer